Patents by Inventor Mette Ladefoged

Mette Ladefoged has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Guanosine Analogues for Use in Therapeutics Polynucleotides
    Publication number: 20230212572
    Abstract: The present invention relates to a polynucleotide that comprises at least one phosphorothioate internucleoside linkage and at least one guanosine analogue comprising a guanine nucleobase analogue selected from the group consisting of: formula (I) and formula (II). Polynucleotides comprising such guanosine analogues show a relative reduced neurotoxicity compared to polynucleotides with natural guanosine.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Inventors: Nanna Albaek, Peter Hagedorn, Mette Ladefoged, Lykke Pedersen, Jacob Ravn
  • Oligonucleotides for modulating ATXN2 expression
    Patent number: 11286485
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: March 29, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged
  • OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
    Publication number: 20210024925
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Application
    Filed: April 3, 2020
    Publication date: January 28, 2021
    Inventors: Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged